EXPRS2 — ExpreS2ion Biotech Holding AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK19.95m
- -SEK26.26m
- SEK12.21m
Annual cashflow statement for ExpreS2ion Biotech Holding AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | SAS | SAS | SAS | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -48.4 | -128 | -106 | -67.7 | -44.3 |
| Depreciation | |||||
| Non-Cash Items | 11.7 | 9.6 | 2.43 | -0.207 | 1.92 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -10.7 | 17.2 | 1.05 | 34 | 1.45 |
| Change in Accounts Receivable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -45.6 | -99.6 | -101 | -33.9 | -40.9 |
| Capital Expenditures | -0.715 | -0.383 | -2.02 | -0.87 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -100 | 106 | 0 | 22.1 | 0 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -101 | 105 | -2.02 | 21.3 | 0 |
| Financing Cash Flow Items | -6.78 | -12.2 | -10.5 | -7.35 | -0.839 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 74.5 | 61.5 | 47.8 | 34.9 | 10.8 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -69.7 | 73.9 | -53.4 | 23.9 | -34 |